Loading...
COVID‐19: Consider IL‐6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients
COVID‐19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 receptor (IL‐6R) antagonist therapy for the COVID‐19 patients. Two humanized monoclonal antibodies are in clini...
Saved in:
| Published in: | J Med Virol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley and Sons Inc.
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7283789/ https://ncbi.nlm.nih.gov/pubmed/32462717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.26078 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|